Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Kondo M, Simon MS, Westblade LF, Jenkins SG, N Babady E, Loo AS, et al. Implementation of infectious diseases rapid molecular diagnostic tests and antimicrobial stewardship program involvement in acute-care hospitals. Infect Control Hosp Epidemiol. 2021;42(5):609-611.

Magro CM, Mulvey JJ, Laurence J, Sanders S, Crowson AN, Grossman M, et al. The differing pathophysiologies that underlie COVID-19-associated perniosis and thrombotic retiform purpura: a case series. Br J Dermatol. 2021;184(1):141-150.

D'Alfonso TM, Pareja F, Paula AD, Vahdatinia M, Gazzo A, Ferrando L, et al. Whole-exome sequencing analysis of juvenile papillomatosis and coexisting breast carcinoma. J Pathol Clin Res. 2021;7(2):113-120.

Plummer JD, Postnikoff SD, Tyler JK, Johnson JE. Selenium supplementation inhibits IGF-1 signaling and confers methionine restriction-like healthspan benefits to mice. Elife. 2021;10.

Gaebler C, Wang Z, Lorenzi JC, Muecksch F, Finkin S, Tokuyama M, et al. Evolution of Antibody Immunity to SARS-CoV-2. bioRxiv. 2021.

Mitchell KF, McElvania E, Wallace MA, Droske LE, Robertson AE, Westblade LF, et al. Evaluating the Rapid Emergence of Daptomycin Resistance in : a Multicenter Study. J Clin Microbiol. 2021;59(4).

Bégin P, Callum J, Heddle NM, Cook R, Zeller MP, Tinmouth A, et al. Convalescent plasma for adults with acute COVID-19 respiratory illness (CONCOR-1): study protocol for an international, multicentre, randomized, open-label trial. Trials. 2021;22(1):323.

Soshnev AA, C Allis D, Cesarman E, Melnick AM. Histone H1 mutations in lymphoma: a link(er) between chromatin organization, developmental reprogramming, and cancer. Cancer Res. 2021.

Yang HS, Costa V, Racine-Brzostek SE, Acker KP, Yee J, Chen Z, et al. Association of Age With SARS-CoV-2 Antibody Response. JAMA Netw Open. 2021;4(3):e214302.

Cho C, Hilden P, Avecilla ST, Barker JN, Castro-Malaspina H, Giralt SA, et al. Combining the Disease Risk Index and Hematopoietic Cell Transplant Co-Morbidity Index provides a comprehensive prognostic model for CD34+-selected allogeneic transplantation. Adv Cell Gene Ther. 2021;4(1).